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Executive Summary
Diabetes and cardiovascular disease have always been a topic of interest. These two
diseases have major known risk factors affecting the lives of these patients. Being enrolled in
the MSN-Nurse Education program, it is important to understand these two diseases and the
known risk factors to provide proper education to patients with type 2 diabetes while reducing
the risk of a cardiovascular event. Cardiovascular disease has been known to be the leading
cause of mortality in patients with type 2 diabetes. With diabetes on the rise in the United States,
it is important to assess changes in these patients to decrease the risk of developing
cardiovascular disease or a major cardiovascular event such as a myocardial infarction, stroke, or
death. The PICOT question addressed in the project is: In patients with type 2 diabetes (P), how
do diet and exercise (I) compared to lipid lowering agents (C) affect cardiovascular disease (O)
at a 3-month evaluation (T)? This is an important topic to address and examine closer since
many Americans are diagnosed with type 2 diabetes. If able to address healthy alternatives to
patients to reduce the risks of major cardiovascular events such as a myocardial infarction or
stroke, it could potentially save many lives. As a nurse educator, it is important to provide
patients with the education they need on proper diet and exercise to make sure they understand
their disease process and how type 2 diabetes can lead to many cardiovascular issues if they do
not take care of their health. If patients will follow a proper diet and exercise, they can decrease
their risk factors and decrease the cholesterol levels without the need for medications.
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Living Healthy with Type 2 Diabetes
Rationale for the Project
In the United States, there is an increase of individuals with type 2 diabetes affecting
more than 100 million people. Patients with type 2 diabetes have a greater risk for developing
cardiovascular disease. In patients, over the age of 65, with diabetes, 68% of those individuals
will die from a cardiovascular event (2015). There are many contributing factors for developing
cardiovascular disease however, diet, obesity, lack of physical activity, and cholesterol levels are
major factors to assess in patients (Martín-Timón et al., 2014). This is a growing problem
especially in the United States as more patients are becoming obese and less active. The
American Heart Association and American Diabetes Association come together as organizations
to create guidelines for patients and providers to decrease the risk of cardiovascular disease in
patients with type 2 diabetes (Croke, 2016). When taking care of patients that have come to the
hospital due to a heart attack or a stroke from poorly controlled diabetes, education is important
to prevent another cardiovascular event. Nurses need to be educated and updated on the
guidelines that American Heart Association and American Diabetes Association provides. The
role of a nurse educator is important in patients with diabetes who are at risk for cardiovascular
disease. In an education setting, nurse educators are the ones providing education to future
nurses. Helping them understand the disease process and how it affects the body is critical for
when they become nurses and care for the increasing patient population who have diabetes. It is
also important for the students to understand cardiovascular disease and how it interacts with
diabetes and affects the arteries in the body. Not only are nurse educators important in the
education setting, but they are also vital in the community. When a patient is newly diagnosed
with diabetes, there is a lifestyle change that needs to take place. Providing the patient with
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appropriate educational classes and materials can help them control the disease and possibly
reduce the risk factors of a future cardiovascular event. Often, patients are diagnosed with
diabetes from their primary care physician. The patient is normally encouraged to try diet,
exercise, and weight loss to see if they can control the diabetes. When the patient returns for
follow up, if they have unsuccessfully been able to maintain blood sugars with diet, exercise, and
weight loss, the primary care will typically start the patient on a diabetic medication. Patients
then return to their everyday lives and may not fully understand the importance of maintaining
proper blood sugars. The patients and families need to realize that it is a lifestyle adjustment.
As nurse educators, we need to be involved in community health events to help bring
awareness of diabetes and cardiovascular disease since many people are affected daily.
Promoting awareness to the physicians and their staff can play a major role in the care of these
patients. Providing patients with a diet regimen and helping them stay on the program can help
prevent worsening of the disease. Patients need to have routine cholesterol screenings performed
since that puts them at a higher risk for an event. Understanding the significance of cholesterol
levels in each patient and providing the appropriate medications could save a patient’s life. If a
patient has been maintaining his or her diabetes but has poorly controlled cholesterol levels, the
patient is at a high risk for specific cardiovascular event such as a myocardial infarction or
stroke. If a patient can follow an appropriate lifestyle, decrease risk factor modifications, and
take their medications, they will greatly reduce the risk of developing cardiovascular disease.
Overall, nurse educators can be a vital source of information to not only the patients, but also the
physicians in detecting the patients who are at risk for cardiovascular disease or major
cardiovascular events.
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Literature Synthesis.
Patients who have diabetes are at a higher risk for developing cardiovascular disease.
They are also at a higher risk for death when compared to the general population. A cohort study
in Sweden looked at 271,174 patients with type 2 diabetes and looked at 5 risk factors: elevated
hemoglobin A1c levels, elevated low-density lipoprotein cholesterol levels, albuminuria,
smoking, and elevated blood pressures. Participants were randomly selected from the Swedish
National Diabetic Registry. The goal of the study was to assess the participants to see if they
were at greater risk of death or a cardiovascular event based on the number of risk factors and if
they were in appropriate range when compared to the control groups. The participants were
followed for a median of 5.7 years. At the conclusion of the study, the participants who were
type 2 diabetic and had risk factors but were all in range when compared to the control group had
no excess risk of death, myocardial infarction, or stroke when compared to the general
population. However, the participants who were type 2 diabetic and had hemoglobin A1c levels
out of the target range were at greater risk for stroke and myocardial infarction. Smoking was
also a major contributor to death in this patient population (Rawshani et al., 2018).
Diabetes continues to be on the rise worldwide and cardiovascular disease is a major
cause of mortality in this patient population. A literature review assessed patient with type 2
diabetes to look at the prevalence rate of cardiovascular disease based on sex, age, duration of
diabetes, body mass index, country. 57 articles were analyzed in the review and included
multiple countries. Overall, cardiovascular disease was prevalent in 32.2% of the patients with
type 2 diabetes and accounts for 50.3% of the deaths in patients with type 2 diabetes (Einarson et
al., 2018). One of the key points from the study is understanding the importance of screening for
cardiovascular disease in patients with type 2 diabetes. Early prevention screening can decrease
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the risk of death or a significant cardiovascular event in these patients. Coronary artery calcium
assessments have been shown to help diagnose those patients with type 2 diabetes who are at
greater risk for cardiovascular disease. Once the patients have completed the test, they can take
appropriate measures such as diet, exercise, or medications once assessed by a physician. The
study does not particularly show any interventions, but it does bring awareness to the growing
population of patients that are being diagnosed with type 2 diabetes and the prevalence of them
having a greater risk for developing cardiovascular disease or a major cardiovascular event such
a stroke, myocardial infarction, or even death.
The Journal of American Cardiology published a clinical review that discussed
prevention of cardiovascular disease in patients with diabetes mellitus. The study was divided
between the different risk factors: lifestyle, exercise, nutrition, and cholesterol management.
Three trials were examined in the review on the effects of exercise in patients with type 2
diabetes: Look-AHEAD, Steno-2 study, and Diabetes Prevention Project. These studies looked
at the effects of different lifestyle changes such as weight loss, physical activity, and diet.
Although there was no direct correlation that that exercise decreases the risk of cardiovascular
disease in patients with type 2 diabetes, it did show combinations of aerobic and resistance
training did lower the hemoglobin A1C levels which gave better glycemic control which helps
decrease the risk of cardiovascular disease. The current guidelines to reduce the risk of
cardiovascular disease in patients with type 2 diabetes regarding physical activity is a moderate
intensity workout for 150 mins or greater per week. Nutrition is important when it comes to
assessing these patients. Counseling patients on the importance of following a proper diet can
reduce the risk of cardiovascular disease. Lipid management is evaluated in the review as a
major risk reduction for cardiovascular disease. The current guidelines state that patients with
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diabetes and have cardiovascular disease risk factors need to be on a high intensity statin. The
clinical review assessed a meta-analysis which included over 18,000 participants with diabetes
from 14 randomized trials using statin therapy. After the mean of 4.3 years there was a 9%
proportional reduction in mortality and 13% mortality reduction in vascular mortality. Overall,
the clinical review demonstrated that diet, exercise, and lipid management did reduce the risk of
cardiovascular disease (Newman et al., 2017).
Another clinical review assessed the effectiveness of statin therapy in diabetic patients to
reduce the risk for cardiovascular disease. The Cholesterol Treatment Trialists’ Collaboration
conducted a meta-analysis in a randomized control trial with statin therapy with 1000 patients.
They were required to take the statin therapy for 2 years for data. The study showed that
lowering the LDL by 2 mmol/L with the effective statin therapy can decrease the risk of a
vascular event in 10% of the participants that were high risk for cardiovascular disease and 5% in
the low- risk population (Collins et al., 2016). Newer classes of cholesterol medications are now
on the market. Current research and data collections are being examined to determine if there is
a cardiovascular reduction using the newer class of statin therapy in addition to a high intensity
statin. Natural supplements have sparked an interest in many people to reduce cholesterol levels
and help control blood glucose. An updated systematic review was studied on the use of
cinnamon and patients with type 2 diabetes. The results showed that patients who consumed
cinnamon on a regular basis over the 4-to-18-week evaluation time had a significant reduction in
the fasting plasma glucose levels, total cholesterol levels, low density lipoproteins (LDL),
triglyceride levels, and an increase in the high- density lipoprotein levels. No significant changes
were noticed on the hemoglobin A1c levels. The study provides supportive data for patients who
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want to add cinnamon supplements to their daily regimen to help reduce blood sugar and
cholesterol levels.
A systematic review of meta-analysis and randomized control trials was conducted using
the Mediterranean diet compared to controlled diets in patients with type 2 diabetes. The
Mediterranean diet is a plant-based diet which helps lower cholesterol levels. At the conclusion
of the systematic review, the Mediterranean diet was effective in lowering the risks of
cardiovascular disease and helped manage glycemic control. The review included 8 metaanalysis and 5 randomized control trials that met criteria. Five of the meta-analysis assessed
cardiovascular risk factors. The studies in the review assessed the Mediterranean diets and
compared it to low fat diets, assessed the reduction in cholesterol levels, and the overall effect on
body weight. At the end of the review, the Mediterranean diet did show to have better glycemic
control and reduction of cardiovascular risk factors when compared to the control diet which
focused on low fats. The Mediterranean diet was proven to be the best option for type 2
diabetics (Esposito et al., 2015). Another study was published regarding the Mediterranean diet.
The study was originally a randomized trial in Spain involving 7,447 participants but later had a
protocol deviation due to not all participants being truly randomized. The study involved
patients with type 2 diabetes who were at risk for cardiovascular disease. There were three diets
implemented in the trial: Mediterranean diet supplemented with extra virgin olive oil,
Mediterranean diet supplemented with mixed nuts, and a control diet which was a reduced fat
diet. The end results of the study showed the patient population who were at high risk for
cardiovascular disease had a lower risk of major cardiovascular events on the Mediterranean diet
supplemented with extra virgin olive and mixed nuts compared to the low-fat control diet
(Estruch et al., 2018).
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Not only is diet and cholesterol management important for decreasing the risk of
cardiovascular disease, but lifestyle changes also need to be assessed. A meta-analysis examined
patients with type 2 diabetes to assess lifestyle changes such as diet, exercise, and education to
see if there is an impact on the clinical markers of cardiovascular disease. 16 randomized control
trial studies were included in the meta- analysis. Each study looked at diabetes education,
supervised exercise programs, and physical activity. The study found that there was
improvement with specific lifestyle interventions such as body mass index, hemoglobin A1c,
systolic blood pressure, and diastolic blood pressure which are associated with the cardiovascular
risk factors. All 16 studies included in the meta-analysis had a decrease in the hemoglobin A1c
levels (Chen et al., 2014). Other articles were reviewed that supported how a proper diet and
exercise can affect the risk factors of cardiovascular disease in patients with type 2 diabetes.
Other studies reviewed looked the effects of cholesterol levels in this patient population. There is
an important aspect with monitoring the cholesterol levels to reduce major cardiovascular events
in this patient population. If patients can decrease the cholesterol levels with the diet and exercise
plan, these patients may greatly benefit if they follow it as prescribed. There are some situations
where patients can follow a special diet and exercise regularly, but they still may need
medications to help reduce a major cardiovascular event due to their genetic make-up. When
patients can understand the process of diabetes and how it interacts with cardiovascular disease,
they will soon realize how important exercise is and how it impacts their lives to decrease the
risk of cardiovascular disease. Helping these patients maintain a healthy lifestyle with diet and
exercise could potentially save their lives from a heart attack, stroke, or death.
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Project Stakeholders
Healthcare providers want to provide the best and safest treatment to your patients that
result in positive outcomes. Safety is number one when it comes to implementing a change in a
practice setting. We do not want to implement a change that can have a negative impact on the
patient. The stakeholder such as the CEO, physicians, nurses, and educators need to understand
the change that will take place and why this change will make a positive outcome on patients. It
is key to make sure if they agree to accept the project in their clinical practice setting, that the
appropriate staff is available to support the project. Nilsen et al. discusses characteristics related
to successful changes. For successful changes, the staff needs to influence the change, prepare
for the change, and value the change. All three of these characteristics can relate to the
stakeholders for positive outcomes (Nilsen et al., 2020). The patients are also the stakeholders at
risk. Some patients may be hesitant to agree to a study because they are not sure of the
unknown. Providing proper education to the patients is important so they know that you are not
there to produce any harm to them but rather want a positive outcome for them in 3 months.
There are many patients that will say that they have had negative side effects when taking a
statin medication. If there is an alternative such as proper diet and exercise to decrease the risk
of cardiovascular disease, many patients will want to trial that option instead of taking a
medication. Franklin et al., performed a recent study relating to person- centered goal setting. It
emphasized the importance of including the patient and healthcare provider to determine the
patient’s goal by working together to achieve a desired outcome (Franklin et al.). This is
important with the patient population because we want to work closely with them to decrease
any major cardiovascular event. I do understand from working directly with patients that have
diabetes, they are already at an increased risk for cardiovascular disease, and some will need the
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additional therapy of cholesterol management and proper diet and exercise to reduce a major
cardiovascular event. However, this change is to examine the effectiveness of diet and exercise
in patients with type 2 diabetes who do not have a history of a major cardiovascular event such
as acute myocardial infarction or stroke.
Implementation Plan
An Internal Medicine Clinic is the anticipated site for implementing the change. The data
needed to warrant a change is to collect a select group of patients that are diagnosed with type 2
diabetes which are at an increased risk for cardiovascular disease. It is important to select
patients that have not had a previous myocardial infarction or stroke. An updated medication list
needs to be collected. Patients currently taking statins for cholesterol need to be placed in a
specific category since part of the assessment is to assess how lipid management can affects
cardiovascular disease. The patients are the stakeholders at risk. Interprofessional collaboration
plays an important role in the process for making an effective change for the patient. Key
professionals involved in the collaboration include the internist, cardiologist, diabetic educator,
nurses, and a research team. The internist is the one who manages the patient’s diabetes on a
regular basis and adjusts his or her medications as needed. The cardiologist will provide the
knowledge and understanding of how diabetes affects cardiovascular disease and how to
decrease the risk of a major cardiovascular event such as a myocardial infarction, stroke, or even
death. A diabetic educator will provide education about the disease process of diabetes and
provide a detailed plan for the patient on proper diet, exercise, and diabetes management to
decrease the risk for developing cardiovascular disease. Nurses will provide support and are the
link of communication. Nurses will assess the patient’s needs and assure patients that they will
receive appropriate care while reinforcing the plan for better health. Nurse researchers provide
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current information on type 2 diabetes and cardiovascular disease. To have access to the clinic,
the internist will need to agree to participate, and the plan will need to be approved by their Chief
Executive Officer. Allies within the organization that can help assist are nurses who work
directly with the physician. With any change process there will always be barriers. Some
barriers could include the Chief Executive Officer who might be hesitant allowing outsiders into
the clinic and the need for participation may not be present among the staff in the clinic. Patients
may not see the importance of the study and they may not be committed to required follow up
appointments due to lack of understanding. Some patients may lack transportation which can
limit access to the appointments.
Ways to eliminate or minimize barriers is to be prepared when approaching the company.
Providing educational information regarding how the patients involved in the change will benefit
overall from the end results. Also, providing educational material on diabetes and cardiovascular
disease to help the staff understand the importance of how these diseases affects patients. Once
access has been gained into the clinic space, it is important to assess the resources to be
successful. Personnel staff would include the nurses and medical assistants. The internist will
oversee the care of the patients. A nurse practitioner can be utilized for the follow up
appointments once the initial visit has been performed. A diabetic educator will play a role in
educating the patients and will develop a plan for the patients to follow during the 3 months.
There is not any specific training needed to help carry out the change. A designated room will
be needed for the patients to be seen and evaluated. A phlebotomist is needed to draw baseline
cholesterol levels and routinely throughout the follow up visits. There will need to be a contract
for the designated laboratory to help with the funding to cover the price of the labs. Consultants
such a cardiologist, dietician, and a personal trainer will be available if needed during the initial
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consult and follow up appointments. The clinic has electronic health records. Proper electronic
health record training and obtaining access to chart within the designated health system will need
to be obtained. The patient consents and labs can be scanned directly into the patient’s chart and
follow up notes will be generated in the charting system. An information technology support
system will be needed as well to make sure the system is working properly. Once the change has
taken place and patients have benefited from the change, the physicians and the nurse clinic staff
will be responsible to carry out the change moving forward. When it comes to the planning
phase, staff engagement is important. When members of the team are engaged in the process,
they take ownership in the project and want the results to be successful (Melnyk & FineoutOverholt, 2019, p. 205-206).
Timetable/Flowchart
The purpose of this project is to examine if appropriate diet and exercise is effective in
reducing the risks of cardiovascular disease in patients with type 2 diabetes when compared to
lipid lowering agents. Due to COVID, I was not able to participate with this project in a facility,
but I will discuss the plan and an estimated timeline for the project. Once the project has been
approved, the first step that needs to be obtained is an acceptance into an internal medicine clinic
would be the ideal location since the patients included in the study are type 2 diabetics. The
patients must have no prior cardiovascular history. There needs to be a group of patients taking
prescribed statins and a non- statin therapy group of patients. The required staff for this project
include an internal medicine physician, a cardiologist, a diabetic educator, dietician, personal
trainer/cardiac rehab nurse, office nurse, medical assistant, and nurse research coordinator. Once
the staff has been selected, proper education is needed for the staff to educate them on the
disease process of diabetes and why these patients are at greater risk for developing
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cardiovascular disease. The internal medicine physician will oversee the care of the patient, but
a nurse practitioner can also be the one to oversee the care of the patient for the remaining follow
up appointments. In the clinic, there will need to be a designated room of the patients to be seen
so it will not disrupt the flow of the regular clinic patients. Electronic health records will be used
for the project. Proper training will be required for the electronic health records and the staff will
need to obtain access to chart within the designated health system. A phlebotomist will need to
be available to draw appropriate labs. A contract will be formed with a local laboratory to run
the labs once drawn and possible work with the study to help cover the price of the lab for the
patient. Consultants such a cardiologist, dietician, and a personal trainer will be available if
needed during the initial consult and follow up appointments. Once the patients have been
selected, the initial visit can be started, and a plan initiated for the patients to follow. Patients
will be followed closely and will be required to come in for follow up appointments. They will
be required to bring in their diet journal and their exercise log for each appointment. Each
month, there will be a team meeting with the staff to discuss the patients progress in detail. It
will also be a time to receive feedback from the staff on how well the process is working and if
anything needs to be revised. At the end of the 3 months, the information will be recorded one
the patient has their final appointment. The patient will complete an evaluation and the outcome
will be assessed to see if the change was effective.
Steps:
•

Week 1: Screen and select patients that meet the criteria (Type 2 diabetic, no known
cardiovascular history, currently taking a statin or not). Schedule a time to consent the
patient for the study so they can begin the initial workup.
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Week 2: Patients will have initial office visit, specific diet and exercise regimen will be
in place, baseline lipid panel obtained, statin documented. Patients will be instructed to
record their food choices and exercise daily.

•

Schedule monthly follow up visits for the next 3 months to assess any cardiovascular
events such as myocardial infarction, stroke, death. Also, document any changes that
have taken place since the last office visit (if any changes). Assess their diet- have the
patient write down their food choices daily and record exercise. Patients will also have
lipid panels drawn monthly.

•

Schedule monthly team visits to assess and evaluate to see if a change is needed for the
next month

•

3-month visit: During the final visit: draw a final lipid panel to compare to baseline,
assess for cardiovascular disease or cardiovascular events (myocardial infarction,
stroke), document if the patient followed the specific diet and exercise regimen. At the
end of the 3-month follow up visit, the patient will receive their incentive for
completing the study.

•

Assess the patient outcomes to determine if a diet and exercise plan was effective for
reducing a major cardiovascular event

18
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Flowchart
*Patients selected
*type 2 diabetic
*Males and Females
*NO history of cardiovascular disease
*Not currently on any statin therapy

Exercise Plan
Patient is placed on a selected diet such
as the Mediterranean Diet

150 minutes per week of moderate
intensity aerobic exercise OR
75 minutes of vigorous intensity exercise

1 Month Follow Up VIsit

Review Diet and Exercise Journal

2 Month Follow up Visit

3 Month/Final Visit

Review Diet and Exercise Journal

FINAL Evaluation

Consult specialist if needed

Consult specialist if needed

Review DIet and Exercise Journal

Has the patient been admitted for
cariovascular rule out?

Has the patient been admitted for
cardiovascular rule out?

Has the patient had any cardiovacular
event within the 3 month period?

Draw Lipid Profile

Draw Lipid Profile

FInal Lipid Profile Drawn

Monitor Vital Signs/Weight

Monitor Vital Signs/Weight

Vital Signs/Weight

Any changes to diet or medications?

Any changes to diet or medications

Final medication list collected

*This flowchart is only for patients who are type 2 diabetics, have no history of cardiovascular
events, and are currently not taking any statin therapy.
*The compared population will be patients who are type 2 diabetics, no history of cardiovascular
disease, but are currently taking statin therapy. This population will have their lipid panel drawn
monthly and will be assessed for any cardiovascular event within the 3- month period. The goal
is to show the effectiveness of proper diet and exercise to reduce the risk of cardiovascular
disease without having to take a statin.

TYPE 2 DIABETES- A CHANGE FOR A BETTER LIFE

19

Data Collection Methods
The data collection for the benchmark project will be collected from the patients at each
follow up visit with their exercise and dietary log. Each patient will have a detailed follow up
appointment each month for 3 months with a nurse practitioner to assess the progression of the
patient during the study. The patient will be interviewed during the visit to assess their progress,
if there has been any hospitalizations, change in medications, or had any cardiac symptoms since
the last visit. Cholesterol levels will be drawn on each patient each month and will be collected
as data. The providers and the staff involved in the study will have scheduled roundtable
meetings to discuss how each of the patients are doing and if there is any areas that need
improvement in the study for the following months. An important concept to remember during
the evaluation period is “Patient Centered Quality Care” (Melnyk & Fineout-Overholt, 2019, p.
218). Patients need to be included in the evaluation phase. They are part of the team and should
be included in the decision making and evaluation phase. Data needed to evaluate if and how the
change has impacted the organization would be to have a debriefing session with the physician,
nurse practitioner, and nursing staff to obtain their thoughts on how the process took place during
the last 3 months. Patient testimonies can be a powerful tool for other patients to read in the
future to gain a better understand on the importance of diabetic management and how to decrease
the risks of a major cardiovascular event with diet and exercise since they are at a greater risk for
developing cardiovascular disease. Education is the key component on how the change affected
the organization. If patients received a clear understanding of the importance and purpose of the
study and are drawn by an incentive at the end of the study, they will be dedicated to completing
the 3 months with routine monthly follow ups and follow the diet and exercise plan. The overall
change for the organization is related to patient care. If the plan is followed appropriately,
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patients will have a decreased risk for cardiovascular disease. Physicians will be able to educate
their patients on the importance of managing their diabetes to reduce the risk of developing
cardiovascular disease. As part of the educational component, providing screenings during
diabetes awareness and cardiovascular disease awareness months can help bring awareness to the
patients and community.
Cost/Benefit Discussion
It is important to remember cost when developing a plan. With any change project, there
are costs are associated with the project. Since I did not have access in the facility for this
project, I have assessed the areas that would have a cost attached. Cost associated with this
project would include the physician fee, nurse practitioner fee if utilizing for follow up
appointments, fees to pay for the nursing staff that are being utilized, rent space, laboratory fees
including the phlebotomist, the price of the lipid panel, and the processing fee, and patient
incentive fee. The overall fee for the items listed above will depend on the price set for each
member of the study. Once the facility has been chosen, a discussion with the administration
needs to take place to determine the price to rent an area in their facility. If able to present the
purpose of the study to the key stakeholders, they may allow the use of an area without any rent
fees associated. It will be important to outline the fees for the physician, nurse practitioner, and
staff involved. There are two options that could be effective with the payments. One option is
that everyone will receive the payment at the end of the 3 months, or second option is that each
person receives a payment each month. This discussion will take place with the office once the
project has been accepted. Each patient involved in the project will receive their incentive at the
end of the 3-month study to make sure they stay active in the study. The long- term cost will be
incorporated in the patient’s normal routine follow up appointment if the change is successful.

TYPE 2 DIABETES- A CHANGE FOR A BETTER LIFE

21

The benefits versus risks/costs analysis will weigh out in the end. Once the start-up is
completed, the remaining fees will include payments for rent, physician/nurse practitioner fee,
staff, and laboratory fees. However, once the change is successful the additional fees will be
included in the patient’s follow up fee and no additional fees will be required. It is difficult to
determine the amount of money that will be saved with the intervention due to this project being
a benchmark project. I would be interested in following up with the project or discussing the
idea with the facility when they start to allow visitors into the facility.
Discussion of Results
This capstone project was performed as a benchmark project this semester due to COVID
restriction at the facility that I was interested in using for my patient selection. It has been a
great experience even though I was not able to perform the study with actual patients. My hope
is that once appropriate patients have been selected for the study that they will benefit greatly
from a diet and exercise plan to reduce the risk of a major cardiovascular event such as a stoke or
myocardial infarction. At this moment, due to the benchmark project, there are no actual results.
There are many prior research articles that support a low- fat, plant- based diet and following an
appropriate exercise program that promotes lowering the risk of cardiovascular disease in patient
with type 2 diabetes. It will be important to note the patients who have a cardiovascular event
while enrolled in the study as this will affect the study outcomes. There are many patients who
do not respond well to statin therapy due to side effects or other complications. If able to show
that a proper diet regimen and exercise plan can be effective for reducing a cardiovascular event,
then these patients will be motivated to follow the plan especially with they are not able to
tolerate statins. There are some patients that require statin therapy due to genetics and a strong
family history of cardiovascular disease. The patients may be able to follow the appropriate diet
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and exercise plan and still require the additional support of taking a high dose statin.
Sustainability is important with a change project. Changes can be meaningful to the patient care
as well as the outcomes. A change project can impose some challenges to the practice or
healthcare setting. With the healthcare setting continuing to change and improve, it is important
to make sure the data is being updated with the times. We need to make sure you are utilizing
the evidence-based practice daily to sustain the change. It is important to make sure we can
sustain the change project, so it does not waste the time and financial investment of the study in
the past (Lennox et al., 2018). There are some questions to brainstorm when determining
whether the project will sustain such as to see if there is clear implementations, is there
commitment from the stakeholders and staff, and financial obligations. Being able to look at the
questions can help determine if the project will sustain (2017). Through the evidence- based
research, it has been shown that proper diet and exercise can reduce the risks of cardiovascular
disease in patients with type 2 diabetes. These patients are already at an increased risk for
developing cardiovascular disease, as a healthcare provider we want to continue to do our best to
provide optimum care for the patients to help the decrease the risks. One way to make sure the
project is sustained is to provide education to the staff and physicians. Physicians, nurses, and
the other staff can provide the patients with the proper resources to make sure they are following
the proper regimen for their diet and exercise plan. Keeping current on the data is a great way to
make sure we are giving the patients the best treatment to prevent cardiovascular disease. It is
often easy to continue the project when everyone is engaged but often once the project is over,
people tend to do back to their original ways of treatment. It is important to make sure the
research, time, and expenses have not been wasted and the change project can continue in the
future.
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Conclusions/Recommendations
With patients diagnosed with type 2 diabetes, education is significant especially from the
time of the initial diagnosis. After extensive research, it has been shown that if a patient will follow
a Mediterranean diet which is a low-fat, plant-based diet and follows the recommended exercise
regiment provided to the patient while monitoring their cholesterol levels, they have a potential to
decrease their risks of cardiovascular disease and major cardiovascular events such as a stroke,
myocardial infarction, or even death. Updated research studies would be beneficial on diet and
exercise for patients with type 2 diabetes and how it affects cardiovascular disease as many studies
are greater than 5 years. For this project, 3 months may not be an effective amount of time to fully
assess the outcomes to determine if these patients will have any cardiovascular events in the future,
but it is a good starting point to monitor the effects for a major event such as a stroke, myocardial
infarction, or even death. Due to COVID restrictions at the facility, this project was performed as
a benchmark project. I am interested in implementing this study in the future to see how the
patients respond with the appropriate diet and exercise plan and monitor the patients to if they have
any cardiovascular events in the future. As a nurse, it is essential to provide patients with all the
resources needed and a plan to promote positive healthy outcomes and wellness with appropriate
diet and exercise in patients diagnosed with type 2 diabetes.
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range 1.33-2.36 and 1.191.58 in secondary
prevention

USPSTF: B
Level of certainty:
Moderate

35

TYPE 2 DIABETES- A CHANGE FOR A BETTER LIFE
bile acid
sequestrants
that are
normally
prescribed
other than
hyperlipidemia,
combo therapy
Rawshani et
al. (2018).
Risk Factors,
Mortality,
and
Cardiovascul
ar Outcomes
in Patients
with Type 2
Diabetes.

Not stated

Cohort

271,174
patients

IV:
Type 2 diabetes

Type 2 diabetes

DV:
Death
Acute
myocardial
infarction
Stroke
Heart failure

Mean follow
up 5.7 years
Randomly
selected from
registry
Attrition rate:
N/A

Not stated

R2
Cox
regression
model

Death from any cause:
smoking (R2 0.020)
Acute myocardial
infarction: glycated
hemoglobin (R2 0.020)
Stroke: glycated
hemoglobin (R2 0.015)
Heart failure: atrial
fibrillation (R2 0.030)
Type 2 diabetics with no
risk factors outside of
range
(hazard ratio, 1.06; 95%
CI, 1.00 to 1.12)
Type 2 diabetics, 80 yrs
and older, no risk factors
out of target range for AMI
(hazard ratio, 0.72; 95%
CI, 0.49 to 1.07)

Strengths:
Type 2 diabetics
Large patient
population
Definitions clear across
the study
Limitations:
Control group not
defined
Not complete
comparison on effects
of treating risk factors
Feasiblility in my
practice: yes
Level of evidence: 4
Level of certainty:
Moderate
USPSTF: B

Type 2 diabetics, no risk
factors outside range- low
risk for AMI
(hazard ratio, 0.84; 95% CI
0.75 to 0.93)
Stroke, no risk factors
outside of range
(Hazard ratio, 0.95; 95%
CI 0.84 to 1.07)
Type 2 diabetics 55yr and
younger, all risk factors out
of target range-high risk
for hospitalization heart
failure
(hazard ratio, 11.35; 95%
CI, 7.16 to 18.01)
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Diabetics with no risk
factors out of range
(hazard ratio, 1.45; 95%
CI, 1.34 to 1.57)

Allen et al.
(2013).
Cinnamon
Use in Type
2 Diabetes:
An Updated
Systematic
Review and
MetaAnalysis

Not stated

Systemat
ic
Review,
Metaanalysis

10 random
control trials
n= 543 patients
Patients with
type 2 diabetes
Left examined:
4-18 weeks

IV:
Cinnamon
suppletment
DV:
HgA1c
LDL
HDL
Triglycerides

No measurements

Risk of
Bias tool

P value of <0.05
DerSimonia
n and Laird
random
effects
model
I2 statistics

Attrition rate:
N/A

CI 95%

Funnel
plots
Egger’s
regression
statistic

I2 statistics: 25%, 50%,
75% represents low,
medium, high degrees
heterogeneity
Regression P values
Potential publication bias
for fasting plasma glucose
analysis (P= 0.004)
Low likelihood for
publication bias on hgA1c,
total cholesterol, LDL,
HDL, triglycerides (P
>0.12 for all)
Fasting plasma glucose
levels:
(-24.59 mg/dL; 95%CI, 40.52 to
-8.67mg/dL)

Strengths:
Type 2 diabetics
Effects on lipid profiles
Limitations:
Small sample size
Different types of
comorbidities
Different forms of
cinnamon
Updated meta-analysis
There was no risk of
harm if the intervention
or findings
No patient had allergic
reaction to cinnamon
Yes this study is
feasible to use in my
practice
Level of Evidence: 1

Total cholesterol:
(-15.60 mg/dL; 95%CI, 29.76 to
-1.44 mg/dL)

Level of Certainty:
Moderate
USPSTF: B

LDL:
(-9.42 mg/dL; 95%CI, 17.21 to
-1.63mg/dL)
Triglycerides:
(-29.59 mg/dL; 95%CI,
1.09 to 2.24mg/dL)
No significant result on
hgA1c

37

TYPE 2 DIABETES- A CHANGE FOR A BETTER LIFE
(-0.16%; 95%, CI -0.39%
to 0.02%)
Chen et al.
(2015).
Effect of
lifestyle
intervention
in patients
with type 2
diabetes: A
metaanalysis.

Not stated

Meta
analysis

16 articles
Patients with
Type 2 diabetes
Number of
patients per
study range 232575
Length of study
range 6months8 years

IV:
Patients type 2
diabetes

No measurements

Random
effect
model
Fixed effect
model

DV:
Body Mass
Index (BMI)
HgA1c
Systolic and
Diastolic
pressure
LDL, HDL

Funnel plot
Fail-safe N
Egger’s test
“Risk of
Bias”
assessment
tool

Attrition rate:
N/A

Q statistics
I2

Results:
Change in BMI
Standardized difference in
means: -0.29
95% CI
(-0.52 to -0.06)
Change in HgA1C
Standardized difference in
means: -0.37
95% CI (-0.59 to -0.14)
Change in systolic and
diastolic blood pressure
Systolic pressure:
Standardize difference in
means: -0.16
95% CI
(-0.29 to -0.03)
Diastolic pressure:
Standardized difference in
means: -0.27
95%CI
(-0.41 to -0.12)
LDL
Standardized difference in
means: -0.14
95% CI
(-0.10 to 0.21)
HDL
Standardized difference in
means: 0.05
95% CI
(-0.29 to 0.02)

Strengths:
Long term effect on
lifestyle interventions
Consitant findings with
other study results
Addresses patient
population for PICOT
question
Limitations:
Different forms of
interventions
Little information
regarding intervention
methodology from the
studies
High risk for bias that
may affect outcomes
Yes for feasibility to
use in my practice
Addresses a patient
population that I
interact with daily
Level of Evidence:
Level 1
Level of Certainty:
Moderate
USPSTF grade: B

High risk for bias in metaanalysis

Esposito et
al. (2015). A
journey into
a
Mediterranea
n diet and
type 2
diabetes: A

Not stated

Systemat
ic
Review
(SR)
MetaAnalysis
(MA)

8 MA and 5
RCT fit the
criteria

IV:
Mediterranean
diet

Random effect
model used.

DV:
Type 2 diabetes
prediabetes

Adults with

No measurements

Q statistics
I2
Begg and
Egger test
stats
Random
effects

Results (95% CI)
Study by Esposito results
Body weight
-1.75 (-2.86 to -0.64)
Study by Nordmann
-2.2 (-3.9 to -0.6)body
weight

First attempt to
summarize data about
the mediterranean diet
on patients at risk or
have type 2 diabetes
Heterogeneity was low
in the studies of a
Mediterranean diet and
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systematic
review with
metaanalyses.

Type 2 diabetes
or were at risk
for type 2
diabetes

model Q
statistics I 2
Stats were
analyzed by
Stata
V.11.0 MA
RCT Forest
Plot
Forest plot
used for
study
results

-7.4 (10.3 to 4.4)cholesterol
Study by AAjala
-1.84 (-2.54 to -1.15)body
weight
-0.41 (-0.58 to 0.24)HbA1c
1.54 (0.38 to 2.71)HDL
Study by Rees
-8.9 (-10.4 to 7.7)cholesterol
Study by Huo
-0.29 (-0.55 to -0.04)body
weight
-0.30 (-0.61 to 0.38)HbA1C
-.5.4 (-7.3 to 3.5)cholesterol
2.31 (0.77 to 3.86)HDL
Study by Carter
-0.30 (-0.61 to 0.03)HBA1C
Study by Koloverou
0.77 (0.66-0.89)Incidence
of diabetes
Study by Schwingshacki
0.81 (0.73 to
0.90)Incidence of diabetes
Study by Esposito(2004)
1.74 (1.36 to
2.21)remission from
metabolic syndrome
Study by Babio
1.32 (1.12 to
1.55)remission of
metabolic syndrome
Sutdy by Toobert
-0.34 (-0.67 to 0.01)HbA1C
Study by Elhayany
-0.28 (-0.63 to -0.07)
HbA1c
Study by Esposito
-0.50 (-0.60 to -0.40)
Study by Salas-Salvado
0.60 (0.43 to 0.85)
0.82 (0.61 to 1.10)

glycemic control in tpe
2 diabetes
More data needs to be
translated in different
popluations to see if
similar results can be
achieved
Overall, the studies
showed Mediterranean
diet did lower
glycosylated
hemoglobin levels and
improved the
cardiovascular risk
factors when compared
to other controlled
diets.
There is no harm to
patients if this diet is
implemented and in fact
it could help them
improve their type 2
diabetes management.
This study could easily
be implemented in the
area of practice since I
work with cardiac
patients and many of
them are diabetics.
Level of evidence:
Level 1
USPSTF grade: A
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Estruch et al.
(2018).
Primary
prevention of
cardiovascula
r disease with
a
Mediterranea
n diet
supplemente
d with extravirgin olive
oil or nuts.

Not stated

Quasi
Experim
ental

7447
participants
Spain
Original report
from 2013 was
said to have
Randomization
Recent report
showed
protocol
deviation on
random
selection
Attrition Rate:
In 2010- 523
participants lost
follow up after
2 or more years

IV:
-Mediterranean
diet with extra
virgin olive oil
-Mediterranean
diet with nuts
-Control diet(
low fat diet)

follow up
evaluations
Year 1-4 follow
up included:
Questionnaires

Cox Model
Sensitivity
analysis

DV:
Incidence of
major
cardiovascular
events
-Myocardial
infarction
-stroke
-cardiovascular
death

-Mediterranean diet with
extra virgin olive oil: End
point of 96 events
-Mediterranean diet with
nuts: End point of 83
events
-Control group: end point
of 109 events
Mediterranean diet extra
virgin olive oil
n=2543
Hazard ratio 0.69
(95% CI, 0.53-0.91)
Mediterranean diet with
nuts
n=2454
Hazard ratio 0.72
(95% CI, 0.54-0.95)
If site B was also excluded
with above popluation
n=5859
Mediterranean diet with
extra virgin olive oil:
Hazard ratio: 0.71
(95% CI, 0.52 to 0.97)
Mediterranean diet with
nuts:
Hazard ratio: 0.68
(95% CI, 0.49 to 0.95)

Strengths:
Large sample size
Close monitoring of
patients and obtaining
objective assessments
Limitations:
Exercise was in the
follow up questionnaire
but was not examined
There were no risk or
harm to the patients
involved in the study.
All participants signed
informed consent.
This trial does provides
good evidence of
maintaining a
Mediterranean diet to
reduce the risk of a
cardiovascular event in
patients with type 2
diabetes. More research
needs to be completed
to determine if similar
outcomes can be
reproduced in different
parts of the world. It
would be a good start in
my practice to
encourage patients to
try tbe Mediterranean
diet to see if it reduces
the risk of a
cardiovascular event.
Level of Evidence: 4
USPSTF grade: B

Einarson, T.
R., Acs, A.,
Ludwig, C.,
& Panton, U.
H. (2018).
Prevalence of
cardiovascula
r disease in

Not stated

Systemat
ic
Literatur
e
Review

57 articles
18 year or older
with T2D
Global

IV:
Adults T2D

No measurements
in review

PRISMA
STROBE

DV:
CVD

4.5million participants
with T2D-overall 32.2%
had prevalence of CVD
Male higher than female
CVD risk
Male/Female combined

Strength:
Global
Large patient
population
Limitation:
Select patient
population
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type 2
diabetes: A
systematic
literature
review of
scientific
evidence
from across
the world in
2007–2017.

Attrition Rate
N/A

CVD
n = 4,289,140
Rate= 32.2%
95% CI (30.0 to 34.4)
Male CVD
n = 241,406
Rate= 27.7%
95% CI (25.3 to 29.9)
Female CVD
n =209,153
Rate = 27.2%
95% CI (22.7 to 31.7)
STROBE checklist-risk of
bias = low
Studies addressed 80% of
STROBE checklist
Mean 80 ± 12%

Legend:
AMI: Acute Myocardial Infarction
BMI: Body Mass Index
CVD: Cardiovascular disease
HDL: high density lipoprotein cholesterol levels
LDL: low density lipoprotein cholesterol levels
MA: Meta- analysis
RCT: Random control trial
SR: Systematic review
T2D: Type 2 Diabetes
CCI: Continuous Care Intervention group
UC: Usual Care group
MACE: Major Adverse Cardiovascular Events
***Prompts for each column – please do not repeat the headings, just provide the data
Used with permission, © 2007 Fineout-Overholt

Some articles were
abstracts
CVD was not described
the the same in the
studies
Level of Evidence: 1
USPSTF: B
Level of Certainty:
Moderate
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Appendix B
Flowchart
*Patients selected
*type 2 diabetic
*Males and Females
*NO history of cardiovascular disease
*Not currently on any statin therapy

Exercise Plan
Patient is placed on a selected diet such
as the Mediterranean Diet

150 minutes per week of moderate
intensity aerobic exercise OR
75 minutes of vigorous intensity exercise

1 Month Follow Up VIsit

2 Month Follow up Visit

3 Month/Final Visit

Review Diet and Exercise Journal

Review Diet and Exercise Journal

FINAL Evaluation

Consult specialist if needed

Consult specialist if needed

Review DIet and Exercise Journal

Has the patient been admitted for
cariovascular rule out?

Has the patient been admitted for
cardiovascular rule out?

Has the patient had any cardiovacular
event within the 3 month period?

Draw Lipid Profile

Draw Lipid Profile

FInal Lipid Profile Drawn

Monitor Vital Signs/Weight

Monitor Vital Signs/Weight

Vital Signs/Weight

Any changes to diet or medications?

Any changes to diet or medications

Final medication list collected

*This flowchart is only for patients who are type 2 diabetics, have no history of cardiovascular
events, and are currently not taking any statin therapy.
*The compared population will be patients who are type 2 diabetics, no history of cardiovascular
disease, but are currently taking statin therapy. This population will have their lipid panel drawn
monthly and will be assessed for any cardiovascular event within the 3- month period. The goal
is to show the effectiveness of proper diet and exercise to reduce the risk of cardiovascular
disease without having to take a statin.
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